<?xml version="1.0" encoding="UTF-8"?>
<p>A second approach to produce a safer YF vaccine is to express the YFV pre-M and E proteins either as recombinant proteins or in another safer viral vector. The most advanced vaccine of this type utilizes the replication-defective Modified Vaccinia Ankara (MVA) vector [
 <xref rid="B132-vaccines-07-00179" ref-type="bibr">132</xref>]. This vaccine has been shown to induce protective immunity in small animal models and is currently being evaluated in a Phase I trial in humans [
 <xref rid="B133-vaccines-07-00179" ref-type="bibr">133</xref>].
</p>
